These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 14520444)

  • 1. First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.
    Wachters FM; Van Putten JW; Kramer H; Erjavec Z; Eppinga P; Strijbos JH; de Leede GP; Boezen HM; de Vries EG; Groen HJ
    Br J Cancer; 2003 Oct; 89(7):1192-9. PubMed ID: 14520444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
    Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
    Hsu C; Kuo SH; Hu FC; Cheng AL; Shih JY; Yu CJ; Lin CC; Huang TC; Yang PC; Yang CH
    Lung Cancer; 2008 Dec; 62(3):334-43. PubMed ID: 18450322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
    Di Maio M; Leighl NB; Gallo C; Feld R; Ciardiello F; Butts C; Maione P; Gebbia V; Morgillo F; Wierzbicki R; Favaretto A; Alam Y; Cinieri S; Siena S; Bianco R; Riccardi F; Spatafora M; Ravaioli A; Felletti R; Fregoni V; Genestreti G; Rossi A; Mancuso G; Fasano M; Morabito A; Tsao MS; Signoriello S; Perrone F; Gridelli C
    J Thorac Oncol; 2012 Dec; 7(12):1830-1844. PubMed ID: 23154555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.
    Gridelli C; Gallo C; Ceribelli A; Gebbia V; Gamucci T; Ciardiello F; Carozza F; Favaretto A; Daniele B; Galetta D; Barbera S; Rosetti F; Rossi A; Maione P; Cognetti F; Testa A; Di Maio M; Morabito A; Perrone F;
    Lancet Oncol; 2007 Jun; 8(6):500-12. PubMed ID: 17513173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
    Danson S; Middleton MR; O'Byrne KJ; Clemons M; Ranson M; Hassan J; Anderson H; Burt PA; Fairve-Finn C; Stout R; Dowd I; Ashcroft L; Beresford C; Thatcher N
    Cancer; 2003 Aug; 98(3):542-53. PubMed ID: 12879472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
    Yang CH; Simms L; Park K; Lee JS; Scagliotti G; Orlando M
    J Thorac Oncol; 2010 May; 5(5):688-95. PubMed ID: 20150825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101).
    Comella P; Filippelli G; De Cataldis G; Massidda B; Frasci G; Maiorino L; Putzu C; Mancarella S; Palmeri S; Cioffi R; Roselli M; Buzzi F; Milia V; Gambardella A; Natale D; Bianco M; Ghiani M; Masullo P;
    Ann Oncol; 2007 Feb; 18(2):324-30. PubMed ID: 17071935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
    Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
    Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
    Michael M; White SC; Abdi E; Nott L; Clingan P; Zimet A; Button P; Gregory D; Solomon B; Dobrovic A; Do H; Clarke S
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):4-14. PubMed ID: 24575793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
    Davies AM; Chansky K; Lara PN; Gumerlock PH; Crowley J; Albain KS; Vogel SJ; Gandara DR;
    J Thorac Oncol; 2009 Jan; 4(1):87-92. PubMed ID: 19096312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer.
    Mok TS; Lam KC; Lee C; Zhang L; Wong H; Chan AT; Yeo W; Yim AP; Chak K; Zee B
    Oncology; 2005; 68(4-6):485-92. PubMed ID: 16020979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
    Syrigos KN; Vansteenkiste J; Parikh P; von Pawel J; Manegold C; Martins RG; Simms L; Sugarman KP; Visseren-Grul C; Scagliotti GV
    Ann Oncol; 2010 Mar; 21(3):556-561. PubMed ID: 19828561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
    Comella P; Frasci G; Panza N; Manzione L; Lorusso V; Di Rienzo G; Cioffi R; De Cataldis G; Maiorino L; Bilancia D; Nicolella G; Natale M; Carpagnano F; Pacilio C; De Lena M; Bianco A; Comella G
    J Clin Oncol; 1999 May; 17(5):1526-34. PubMed ID: 10334540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.
    Reck M; Socinski MA; Luft A; Szczęsna A; Dediu M; Ramlau R; Losonczy G; Molinier O; Schumann C; Gralla RJ; Bonomi P; Brown J; Soldatenkova V; Chouaki N; Obasaju C; Peterson P; Thatcher N
    J Thorac Oncol; 2016 Jun; 11(6):808-18. PubMed ID: 26980471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
    Zhang L; Zhang Y; Li N; Xu F; Pan ZK; Guan ZZ
    Ai Zheng; 2004 Nov; 23(11 Suppl):1455-8. PubMed ID: 15566656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
    Movsas B; Langer CJ; Ross HJ; Wang L; Jotte RM; Feigenberg S; Xu F; Huang CH; Monberg MJ; Obasaju CK
    J Thorac Oncol; 2010 May; 5(5):673-9. PubMed ID: 20354453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life.
    Jassem J; Krzakowski M; Roszkowski K; Ramlau R; Słomiński JM; Szczesna A; Krawczyk K; Mozejko-Pastewka B; Lis J; Miracki K
    Lung Cancer; 2002 Jan; 35(1):73-9. PubMed ID: 11750716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
    Ohe Y; Ohashi Y; Kubota K; Tamura T; Nakagawa K; Negoro S; Nishiwaki Y; Saijo N; Ariyoshi Y; Fukuoka M
    Ann Oncol; 2007 Feb; 18(2):317-23. PubMed ID: 17079694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.